Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381348 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30673511 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29725684 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29403553 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30067164 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30678552 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL24632196 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL31114965 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29330492 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL13663954 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238252-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238248-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4337193-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | Biogen MA Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20220023265-A1 | USE OF INHIBITORS OF PHOSPHATASE ACTIVITY OF SOLUBLE EPOXIDE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE (FR) | 2022-01-27 | — | — | US | disclosed |
| US-20200140450-A1 | CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD | SHOWA UNIVERSITY (JP) | 2020-05-07 | — | — | US | disclosed |
| US-8883462-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883462-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120100579-A1 | TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER | TOKYO UNIVERSITY OF AGRICLATURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20120100579-A1 | TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER | TOKYO UNIVERSITY OF AGRICLATURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-8110596-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110596-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140450-A1 | CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD | TST, SMS, TMSB4X | ALOX5 4654/4885APP 1534/4885PTPN1 3693/4885 |
| US-20240238248-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | PSD, SCN7A, MBOAT7 | ALOX5 3129/4885APP 1162/4885PTPN1 1836/4885 |
| US-20220023265-A1 | USE OF INHIBITORS OF PHOSPHATASE ACTIVITY OF SOLUBLE EPOXIDE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | NCEH1, PPME1, EPHX1 | ALOX5 575/4885APP 2572/4885PTPN1 124/4885 |
| US-20240238252-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | SMPD1, SMPD3, MBOAT7 | ALOX5 2914/4885APP 695/4885PTPN1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.